Next Phase Newsletter

A healthcare-focused investment firm had its beginnings as a CRO, helping companies execute clinical trials. This is still an important component of the firm’s unique business model, but in addition to this, the firm now seeks to actively invest in promising projects like a traditional venture capital fund. In addition to investing in companies, the firm seeks to leverage its capabilities to help companies with clinical trials in Central Asia. Executing clinical trials in Central Asia is much cheaper, allowing companies to validate their technologies on a faster, efficient basis. The firm is capable of investing $15-20M over the company’s lifecycle, and seeks companies globally.
Within life sciences, the firm seeks opportunities in therapeutics and medtech. Ideally, the firm seeks to engage in companies who are in early clinical stage – beyond Phase I – but is open to engaging with earlier projects. The firm is opportunistic in term of subsector and indication.

The firm seeks companies backed by innovative science and experienced management teams. As mentioned earlier, the firm is equipped to help companies execute clinical trials on a faster, more efficient basis, and has deep relationships with regional governments and leading institutions to make this possible.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in the US with additional offices in China has built three arms to support their portfolio companies, which is broken down to the following: (1) Investment: The firm invests in early-stage life science ventures, from Seed to Series B, with Series A and Series B being the firm’s sweet spot. Typical size of investment ranges from $1-2M in seed stage companies, and $3-5M in venture round companies. (2) Advisory Service to C-Suite: The firm supports entrepreneurs to expand to the Chinese market, and the firm has multiple offices in China and needed expertise to support the entrepreneur’s vision. (3) Analytics arm: The firm plays a fundamental role in deal sourcing and market trend analysis based on their proprietary data platform. Currently, the firm is most interested in companies based in USA, Israel, and Western Europe, particularly companies in the Nordic region.
The firm will consider therapeutics, medical devices, diagnostics, and life science tools. The firm is most interested in medical devices, and their interests include medtech and biotech combination products, novel methods of drug delivery, in vitro diagnostics (novel instruments and reagents), etc. The firm is interested in both 510K and PMA devices. Within therapeutics, the firm is more interested in clinical assets and typically do not look at pre-clinical companies unless the opportunity is compelling. Current main indication areas of interest for the firm are cardiovascular disease, oncology, and women’s health.

The firm seeks to work with management teams who are passionate about their technology and dedicated to creating values for the larger community. Though the firm is able to support companies who are interested in entering the China market, having a China angle is not necessary for investment. The firm can act as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Through a network of strategic limited partners that includes leading providers, payers, and vendors, a USA-based venture capital platform applies industry knowledge and operational experience to early-stage companies focused on innovation. The firm’s most recent fund actively pursues Seed, Series A, Series B, and Series C stage investments. The firm’s exclusive focus is helping to transform healthcare by forging partnerships among its network members and the entrepreneurs addressing the industry’s biggest challenges and opportunities.

The firm pursues venture-stage investments in technology-based businesses in the healthcare sector, including but not limited to software, software-as-a-service, digital health solutions, technology-enabled services, clinical services, diagnostic tools, and medical devices. As an experienced life-cycle investor, the firm actively pursues Seed, Series A, Series B, and Series C stage investments.

The firm looks for privately held companies with experienced management teams. The firm looks to work side by side with entrepreneurs helping them form strategic relationships, recruit management talent, and assemble vital resources necessary for growth.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with several offices throughout the US has raised five investment funds since inception. Its most recent fund closed in 2021. The firm typically makes equity investments in U.S.-based companies, with portfolio companies located on both coasts and throughout the central part of the country. The firm will consider investing at all stages, with a focus on seed and early-stage investments, including founding companies. Investment size is up to $20 million throughout a portfolio company’s path to liquidity.

The firm is currently looking for new investment opportunities in the life science space, with a specific focus on biopharmaceuticals and therapeutic medical devices. The firm has invested in biopharmaceutical companies focused on developing drugs to treat enteral feeding intolerance and disorders that are driven by CD47-mediated signaling pathways, including leukemia, lymphoma, solid tumors, and pulmonary hypertension. In addition, the firm has invested in a medical device developing a minimally-invasive, catheter-based device to re-create valves in deep leg veins. The firm does not look at diagnostics, though may be interested in technology with real-time feedback for procedures.

The firm focuses on identifying and shaping early-stage life science companies in the series A/B rounds to create significant shareholder value. Because of its extensive operating expertise, the firm is able to help entrepreneurs achieve near-term objectives that position their companies for exit.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Venture Capital firm based in the US typically invests between $3-5M initially and $6M to $10M over the lifetime of the investment. Investments are generally in the form of milestone based equity tranches, however the firm also has experience in working with convertible notes.

The firm is currently looking for early stage companies in the Therapeutics, Diagnostics, Medical Device and Healthcare IT spaces. In the Therapeutics space, the firm is opportunistic in terms of subsector but is most interested in indications of Ophthalmology, Cardiovascular, Pulmonary, Anti-Infectives, Metabolic Disorders, Renal Diseases, Oncology, Immunology, Dermatology, and Orphan Diseases. For companies developing therapeutics, the firm is looking for companies primarily with a lead product in preclinical trials, although they will consider companies with products having recently entered Phase I.

In the Medical Device space, the firm strongly prefers that the company at least has an early prototype of their product and the firm is opportunistic in terms of medical device subsector and is open to all classes of device.

In Healthcare IT, the firm is interested in three specific areas: (1) modernizing operations with innovative delivery models, insurance products and clinical trial automation, (2) technology that drive precision in care personalization/targeted therapy and enhanced disease and care management tools, (3) IT empowering patients and caregivers with health education, price/quality transparency, health surveillance and biometric monitoring for enhanced senior care.

For Healthcare IT investments, the firm looks only at post-revenue companies. For drug and device deals, however, the firm only invests in pre-revenue companies and often works with spinouts directly from universities, though this is not a requirement as the firm is open to all types of early stage companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in Western Europe is currently investing out of their first fund and looks to invest in early-stage life science companies in the therapeutics space. The firm focuses on Seed investments in the form of equity. Typical allocation is up to $5M for the first ticket. Forty51 Ventures invests in European companies but is open to global opportunities.

The firm is interested in therapeutics, with a focus on oncology, immunology, rare diseases, fibrotic diseases and CNS. The firm will invest in pre-clinical therapeutic companies.

The firm has no specific company or management team requirements and is willing to work with all early-stage companies globally, with promising technologies. The firm prefers to lead investments and seeks board seat representation.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.